Home›Oncology› Dermatomyositis with breast cancer regresses on glucocorticoids and paclitaxel in single case
Dermatomyositis with breast cancer regresses on glucocorticoids and paclitaxel in single caseNew findings link dermatomyositis and breast cancer in one patient
Frontiers in MedicinePublished September 19, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider malignancy screening in dermatomyositis not responding to standard therapy.
This is a single case report describing a 48-year-old woman with dermatomyositis and breast cancer. The report is not a controlled study and does not report a comparator, primary outcome, follow-up duration, or safety data.
The patient received glucocorticoids, paclitaxel, platinum-based agents, radical breast surgery, and adjuvant radiotherapy. According to the report, her skin lesions markedly regressed, muscle strength improved, and dysphagia was significantly alleviated. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for these outcomes.
The authors note that the single case report is a limitation and that the findings cannot be used to generalize treatment efficacy or risk factors for the broader population. Adverse events, serious adverse events, discontinuations, tolerability, funding, and conflicts of interest were not reported.
The report highlights the importance of screening for underlying malignancies in patients with dermatomyositis, especially those who do not respond to standard therapy. Clinicians should interpret this as a hypothesis-generating observation only, not as evidence of a causal or generalizable treatment effect.
How this fits prior evidence
This case report is consistent with the practice of screening for underlying malignancy in dermatomyositis, particularly in patients not responding to standard therapy. It does not confirm or extend prior coverage of sacituzumab govitecan in metastatic breast cancer, SGRT/OSMS assisted DIBH in left-sided breast radiotherapy, tumor necrosis-related fever during neoadjuvant chemoimmunotherapy, virtual reality for perioperative anxiety and pain, or oncoplastic breast-conserving surgery for margin control. As a single case report, it addresses a gap in describing a possible association between dermatomyositis and breast cancer but cannot establish causality or treatment efficacy.
Imagine dealing with dermatomyositis, a condition that causes muscle weakness and skin issues, only to find out it is linked to an underlying cancer. This is the reality for a 48-year-old woman who faced both dermatomyositis and breast cancer simultaneously.
Doctors treated her with a combination of glucocorticoids and paclitaxel, along with surgery and radiation. Following this treatment, the woman saw a marked improvement. Her skin lesions regressed, her muscle strength increased, and her difficulty swallowing, known as dysphagia, was significantly eased.
While this story is just one case, it highlights a vital point for doctors. It shows why it is so important to screen for hidden cancers in patients with dermatomyositis, especially when they do not respond to standard treatments. Because this is a single case report, we cannot say it applies to everyone, but it serves as a clear reminder to look deeper when a patient's condition stays stubborn.
What this means for you:
A single case shows that treating underlying cancer can improve symptoms for patients with dermatomyositis.
Common questions
What symptoms improved in this patient?
The patient experienced a marked regression of skin lesions, an improvement in muscle strength, and a significant relief from dysphagia, which is the medical term for difficulty swallowing.
What treatments were used for this condition?
The patient received glucocorticoids and paclitaxel, along with platinum-based agents, radical breast surgery, and adjuvant radiotherapy.
Why is this case important for other patients?
This case highlights why doctors should screen for underlying malignancies, like cancer, in patients with dermatomyositis who do not respond to standard therapies.
BackgroundCancer-associated dermatomyositis (CADM) is a rare paraneoplastic syndrome characterized by inflammatory myopathy and distinctive cutaneous manifestations. Early recognition of an underlying malignancy is essential for improving patient outcomes.Case presentationWe report the case of a 48-year-old woman who initially presented with dermatomyositis as the first manifestation of breast cancer. She was admitted with progressive dysphagia, violaceous edematous erythema involving the face and neck, and proximal muscle weakness of the extremities. The patient had previously been diagnosed with idiopathic dermatomyositis at another institution and treated with glucocorticoids; however, her symptoms showed no significant improvement. Further evaluation at our hospital revealed markedly elevated muscle enzyme levels. Autoantibody testing demonstrated weak positivity for anti-Jo-1 antibodies and positivity for anti-Ro-52 antibodies. Both skin and muscle biopsies supported the diagnosis of dermatomyositis. Comprehensive malignancy screening subsequently identified invasive carcinoma of the right breast with axillary lymph node metastasis. Following treatment with glucocorticoids combined with two cycles of neoadjuvant chemotherapy consisting of paclitaxel and platinum-based agents, the patient’s skin lesions markedly regressed, muscle strength improved, and dysphagia was significantly alleviated. She subsequently underwent radical breast surgery followed by adjuvant radiotherapy, and her condition has remained stable during follow-up.ConclusionA review of the literature indicates that age >40 years, dysphagia, rapid disease progression, and positivity for anti-transcription intermediary factor 1-gamma anti-TIF1-γ antibodies are important risk factors for CADM. Thorough malignancy screening should be performed in all newly diagnosed patients with dermatomyositis, particularly for common associated malignancies such as breast cancer, lung cancer, ovarian cancer, and nasopharyngeal carcinoma. Clinicians should maintain a high index of suspicion for occult malignancy in patients who respond poorly to conventional dermatomyositis therapy. Early identification and effective treatment of the underlying malignancy are critical for improving the prognosis of CADM.
